HDAC-IN-30
Modify Date: 2025-08-21 11:17:39
HDAC-IN-30 structure
|
Common Name | HDAC-IN-30 | ||
|---|---|---|---|---|
| CAS Number | 2756809-34-2 | Molecular Weight | 405.45 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H23N5O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of HDAC-IN-30HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC50=13.4 nM),HDAC2 (IC50=28.0 nM), HDAC3 (IC50=9.18 nM), HDAC6 (IC50=42.7 nM), HDAC8 (IC50=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy[1]. |
| Name | HDAC-IN-30 |
|---|
| Description | HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC50=13.4 nM),HDAC2 (IC50=28.0 nM), HDAC3 (IC50=9.18 nM), HDAC6 (IC50=42.7 nM), HDAC8 (IC50=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy[1]. |
|---|---|
| Related Catalog | |
| Target |
HDAC1:13.4 nM (IC50) HDAC2:28.0 nM (IC50) HDAC3:9.18 nM (IC50) HDAC6:42.7 nM (IC50) HDAC8:131 nM (IC50) |
| In Vitro | HDAC-IN-30 (compound 8 h; 0.5, 1, 2 μM; 48 hours) can effectively activate the p53 pathway by promoting the phosphorylation of p53[1].HDAC-IN-30 (0, 1, 2.5, 5 mM; 48 hours; HepG2 cells) induces cell cycle arrest at the G2 phase in a concentration-dependent manner[1].HDAC-IN-30 (0, 1, 2.5, 5 mM; 48 hours) possesses prominent anticancer activity in HepG2 cells[1]. Western Blot Analysis[1] Cell Line: HepG2 cells Concentration: 0.5, 1, 2 μM Incubation Time: 24 hours Result: Could effectively activate the p53 pathway by promoting the phosphorylation of p53 Cell Cycle Analysis[1] Cell Line: HepG2 cells Concentration: 0, 1, 2.5, 5 μM Incubation Time: 48 hours Result: Cells were arrested at the G2 phase in a dose-dependent manner. Apoptosis Analysis[1] Cell Line: HepG2 cells Concentration: 0, 1, 2.5, 5 μM Incubation Time: 24 hours Result: Possessed prominent anticancer activity in HepG2 cells. |
| In Vivo | HDAC-IN-30 (12, 24 mg/kg; intraperitoneal injection, every two days for 4 weeks) exhibits potent anticancer activity and no side effects even at high dose (24 mg/kg)[1]. Animal Model: HepG2 xenograft mouse model[1] Dosage: 12, 24 mg/kg Administration: Intraperitoneal injection, every 2 days, 4 weeks Result: Exhibited potent anticancer activity |
| References |
| Molecular Formula | C22H23N5O3 |
|---|---|
| Molecular Weight | 405.45 |